Drug intelligence / Profile preview

NF-κB decoy oligodeoxynucleotide

Development stage: Unknown
Lead developer: AnGes
Modality: RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
Administration: Injection, Topical Ointment, High-intensity Ultrasound-microbubble Method

Overview

NF-κB decoy oligodeoxynucleotides are synthetic double-stranded oligonucleotides containing the κB consensus sequence. They function by competitively binding to NF-κB proteins, thereby preventing NF-κB from interacting with its target gene promoters and inhibiting NF-κB-mediated gene expression. This mechanism is used to suppress inflammatory cytokines and adhesion molecules, which are crucial in various inflammatory and autoimmune diseases[2][3][5].

Other names: NF-κB decoy oligonucleotide

Targets

NF-κB

Beyond the preview

Go deeper on NF-κB decoy oligodeoxynucleotide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NF-κB decoy oligodeoxynucleotide.

Explore the full profile